PTJ
LXEO icon

Paul Tudor Jones’s Lexeo Therapeutics LXEO Stock Holding History

Paul Tudor Jones’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-132,187
Closed -$2.12M – 2942
2024
Q2 		$2.12M Buy
+132,187
New +$1.92M 0.01% 1031

Other funds holding LXEO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DCP
D1 Capital Partners New York $34.8B AUM 11.34% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Paul Tudor Jones's LXEO Position: Q3 2024 in Review

Paul Tudor Jones sold out of Lexeo Therapeutics (LXEO) in Q3 2024, closing a stake of 132,187 shares — an estimated $2.12M sold.

Paul Tudor Jones first reported a position in LXEO in Q2 2024 and held it in 1 quarter. The position peaked at $2.12M in Q2 2024. 69 funds tracked by Wall St. Rank hold LXEO as of Q3 2024.

  • Paul Tudor Jones reported no remaining Lexeo Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Paul Tudor Jones sold 132,187 Lexeo Therapeutics shares in Q3 2024, an estimated $2.12M.
  • Paul Tudor Jones first reported a position in Lexeo Therapeutics in Q2 2024 and held it in 1 quarter.
  • Paul Tudor Jones's Lexeo Therapeutics position peaked at $2.12M in Q2 2024.
  • 69 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2024.

Based on Tudor Investment Corp's 13F filing for Q3 2024, filed 14 Nov 2024.